MY SITE
  • Home
  • General Information
    • Welcome
    • Top 10 Reasons to Attend
    • 2021 Program Committee
    • Board of Directors
    • Contact CRS
    • Code of Conduct
  • Program, Abstracts, & Speakers
    • Conference Program >
      • Tech Forums
      • Workshops
    • Invited Speakers
    • Abstract Submissions
    • Special Groups >
      • Consumer & Diversified Products Division
      • Women in Science
      • Young Scientist Committee
  • Industry Involvment
    • Exhibit & Sponsor Pricing
    • Workshops
    • 2021 Sponsors & Exhibitors
    • Corporate Membership
  • On-Demand Pricing
Industry Roundtable on Pharmaceutical Nanoformulations
Tech Session 2
Sponsored By: 
Picture
The impact of nanotechnology on pharmaceuticals has been demonstrated in numerous ways, including
targeted cancer treatments, mRNA vaccines, intracellular siRNA delivery, antifungal therapies and other
treatments that leverage the power of nanoscale phenomena. Critical to the success of these
approaches is how the pharmaceutical formulation controls the size, shape, composition, stability,
biocompatibility and overall function of the nanomedicine. Even with careful design of these critical
attributes, success of the resulting nanomedicine is often hindered by challenges in the scale-up of
manufacture, difficulties in characterizing nanoformulations, quality control, and resulting challenges in
meeting regulatory requirements.

In this Industry Roundtable, a panel of experts will address five critical questions associated with
nanoformulation design, manufacturing, characterization and applications.

1. How are we exploiting the unique capabilities of nanoformulations in Pharma?
2. What challenges does manufacturing of nanoformulations present and how can they be
addressed?
3. What are the challenges of nanoformulations characterisation and how can they be addressed?
4. What are the regulatory requirements for nanoformulations characterisation and how are they
met?
5. How will nanoformulations make the greatest impact on medicine in the coming decade?
​
A panel member will take the lead on answering each question, followed by additional views and
commentary from the other panelists. The session is designed for significant interaction among the
panelists, as well as for questions and discussion by the session attendees.
Picture
Marianne Ashford
Astrazeneca
​
​
Senior Principal Scientist
​

Picture
Jeffrey Clogston
National Cancer Institute
Principal Scientist
​
​

Picture
Laura Pala
Oxford HighQ
​
Business Development Scientist
Picture
Franck Pavan
V-nano
​

General Manager

​

Powered by Create your own unique website with customizable templates.
  • Home
  • General Information
    • Welcome
    • Top 10 Reasons to Attend
    • 2021 Program Committee
    • Board of Directors
    • Contact CRS
    • Code of Conduct
  • Program, Abstracts, & Speakers
    • Conference Program >
      • Tech Forums
      • Workshops
    • Invited Speakers
    • Abstract Submissions
    • Special Groups >
      • Consumer & Diversified Products Division
      • Women in Science
      • Young Scientist Committee
  • Industry Involvment
    • Exhibit & Sponsor Pricing
    • Workshops
    • 2021 Sponsors & Exhibitors
    • Corporate Membership
  • On-Demand Pricing